Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Alpha Tau Medical Ltd has a consensus price target of $13.6 based on the ratings of 5 analysts. The high is $23 issued by Cantor Fitzgerald on August 29, 2023. The low is $7 issued by Piper Sandler on August 15, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on October 23, 2024, October 11, 2024, and August 20, 2024, respectively. With an average price target of $9 between HC Wainwright & Co., there's an implied 292.16% upside for Alpha Tau Medical Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Alpha Tau Medical (NASDAQ:DRTS) was reported by HC Wainwright & Co. on October 23, 2024. The analyst firm set a price target for $9.00 expecting DRTS to rise to within 12 months (a possible 292.16% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Alpha Tau Medical (NASDAQ:DRTS) was provided by HC Wainwright & Co., and Alpha Tau Medical reiterated their buy rating.
There is no last upgrade for Alpha Tau Medical
There is no last downgrade for Alpha Tau Medical.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alpha Tau Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alpha Tau Medical was filed on October 23, 2024 so you should expect the next rating to be made available sometime around October 23, 2025.
While ratings are subjective and will change, the latest Alpha Tau Medical (DRTS) rating was a reiterated with a price target of $9.00 to $9.00. The current price Alpha Tau Medical (DRTS) is trading at is $2.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.